

AMENDMENT

Listing of Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1.-39. (Canceled)

40. (Currently Amended) The method of claim ~~[[39]]48~~, wherein said azido-labeled compound is azido ~~dipyrodiazepinona~~ dipyridodiazepinona or *N*-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furanocarbothiamide.

41. (Currently Amended) The method of claim ~~[[39]]48~~, wherein said azido-labeled compound is *N*-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furanocarbothiamide.

42. (Previously Presented) The method of claim 48, wherein the irradiation is with UV light.

43. (Currently Amended) The method of claim 48, wherein ~~reverse transcriptase is comprised in the viral particle~~ is an HIV particle.

44. (Previously Presented) The method of claim 43, wherein said HIV particle is HIV-1.

45. (Previously Presented) The method of claim 44, wherein said HIV-1 is Group M or Group O.

46. (Previously Presented) The method of claim 45, wherein said Group M are selected from the group consisting of clade A, clade B, clade C, clade D, clade E, clade F, clade G, clade H, and clade I.

47. (Previously Presented) The method of claim 45, wherein said Group M particles are clade B particles.

48. (Currently Amended) A method of eliciting an immune response comprising:
obtaining a viral particle comprising a reverse transcriptase that has been inactivated by
binding said reverse transcriptase with one or more azido-labeled compounds and
then irradiating said reverse transcriptase; and
administering the viral particle ~~the inactivated reverse transcriptase~~ to a subject, wherein
an immune response is elicited in the subject.
49. (Previously Presented) The method of claim 48, wherein the subject is human.
50. (Previously Presented) The method of claim 49, further defined as a method of
vaccination.
- 51.-56. (Canceled)